Navigation Links
Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease
Date:1/13/2014

STOCKHOLM, Jan. 13, 2014 /PRNewswire/ -- Wilson Therapeutics, a privately-held biopharmaceutical company, today announced that it has successfully filed an Investigational New Drug (IND) application with U.S. Food and Drug Administration for the development of WTX101 (bis-choline tetrathiomolybdate), a novel de-coppering agent under evaluation as a treatment for Wilson Disease. The recent acceptance of the U.S. IND is a key initial step in the company's plan to advance WTX101 into pivotal clinical trials as a treatment for Wilson Disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damages.

"This IND enables us to proceed with a Phase 1 study that will provide additional pharmacokinetic and bioavailability data to support the overall development of WTX101 as it moves towards late stage, pivotal trials," said David Clark, M.D., chief medical officer of Wilson Therapeutics. "We expect to conduct this study quickly as we advance the WTX101 program forward this year."

WTX101 is the proprietary bis-choline formulation of tetrathiomolybdate (TTM), which has been evaluated in clinical studies in over 500 patients in various indications. TTM has been shown to rapidly lower copper levels. Previous data also suggest that TTM may stabilize neurological function and reduce the risk of neurological deterioration after initiation of treatment in Wilson Disease patients with neurological disease. WTX101 has also been tested in oncologic clinical trials and was shown to be safe and tolerable while efficiently lowering copper levels with once-daily dosing. WTX101 has received orphan drug designation in both the United States and the European Union.

"There remains a serious unmet need in the treatment of Wilson Disease patients, particularly those who present with neurological symptoms that are often suboptimally treated with currently approved medications," said Fred Askari, M.D., Ph.D., associate professor and director of the Wilson Disease Program and Wilson Disease Center of Excellence, Division of Gastroenterology in the Department of Internal Medicine at the University of Michigan.  "We need to develop treatments that are more tolerable and convenient, and can be used at all phases of the disease."

About Wilson Therapeutics
Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson Disease through development of new treatment options and support for increased awareness and education about Wilson Disease. Wilson Therapeutics' lead product candidate, WTX101, is currently in clinical development as a treatment for Wilson Disease, a serious orphan disease that affects approximately 1 in 15,000 worldwide. Wilson Therapeutics was founded by Healthcap, one of the largest venture capital firms in Europe specialized in life sciences.  Visit www.wilsontherapeutics.com for more information.


'/>"/>
SOURCE Wilson Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wilson Sonsini Goodrich & Rosati Elects Four New Partners
2. Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
3. TrialNetworks Customer Steve Sweeney of Arteaus Therapeutics Encourages Clinical Trial Sponsors to Treat Investigative Sites Like Customers by Using Innovative Technology
4. Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
5. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
6. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline
7. Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
8. Todd Rider Joins Draper to Continue Antiviral Therapeutics Development
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
11. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... City, Missouri (PRWEB) , ... May 27, 2016 , ... ... Development Manager, Turf and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave ... Herbicide Product Manager, where he was integral in the development and launch of many ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... state, but investors playing in this space know that volatility ... this morning,s featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... CTIC ), Lpath Inc. (NASDAQ: LPTN ), and ... now and gain access to the technical alerts for these ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... 26, 2016 , ... Kinder Scientific (KinderScientific.com), a leading animal ... the Company for the future. Kinder Scientific announces restructured ownership and additional ... appointed Chairman of the Board, Curtis D. Kinghorn has been appointed CEO/President and ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):